D-erythro-Sphingosine-13C2, d2

D-erythro-Sphingosine-13C2, d2 is a deuterated labeled D-erythro-Sphingosine[1]. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC) . D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[2][3][4][5].

Product Specifications

CAS Number

[2692623-81-5]

Product Name Alternative

Erythrosphingosine-13C2, d2; erythro-C18-Sphingosine-13C2, d2; trans-4-Sphingenine-13C2, d2

UNSPSC

12352211

Target

Endogenous Metabolite; Isotope-Labeled Compounds; Phosphatase; PKC

Type

Isotope-Labeled Compounds

Related Pathways

Epigenetics; Metabolic Enzyme/Protease; Others; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

CCCCCCCCCCCCC/C=C/[C@@H](O)[13C@@H](N)[13C]([2H])([2H])O

Molecular Formula

C16 13C2H35D2NO2

Molecular Weight

303.49

References & Citations

[1]Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359 (1-2) :48-56.|[2]Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 (Pt 3) :699-703.|[3]Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N, N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172 (2) :683-91.|[4]Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30 (1) :22-7.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.